Search research articles
Contact Us
Filters
Showing results (221-230 of 280) with videos related to
Page
of 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2004
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
John Rinehart, Alex A Adjei, Patricia M Lorusso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2013
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma
Jennifer R Diamond, Ravi Salgia, Marileila Varella-Garcia, et al.
British Journal of Cancer
|
October 4, 2017
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
K P Papadopoulos, B F El-Rayes, A W Tolcher, et al.
Scientific Reports
|
May 11, 2018
Evaluation of pre-analytical factors affecting plasma DNA analysis
Havell Markus, Tania Contente-Cuomo, Maria Farooq, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 28, 2010
Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications
Christopher P Leamon, Joseph A Reddy, Patrick J Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2014
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Channing J Paller, Penelope A Bradbury, S Percy Ivy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2011
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors
Patricia M LoRusso, Charles M Rudin, Josina C Reddy, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
Amita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2021
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Florence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2016
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Daniel D Von Hoff, Monica M Mita, Ramesh K Ramanathan, et al.
Page
of 28
Search research articles
Search
Showing results (221-230 of 280) with videos related to
Sort By:
Page
of 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2004
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
John Rinehart, Alex A Adjei, Patricia M Lorusso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2013
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma
Jennifer R Diamond, Ravi Salgia, Marileila Varella-Garcia, et al.
British Journal of Cancer
|
October 4, 2017
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
K P Papadopoulos, B F El-Rayes, A W Tolcher, et al.
Scientific Reports
|
May 11, 2018
Evaluation of pre-analytical factors affecting plasma DNA analysis
Havell Markus, Tania Contente-Cuomo, Maria Farooq, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 28, 2010
Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications
Christopher P Leamon, Joseph A Reddy, Patrick J Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2014
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Channing J Paller, Penelope A Bradbury, S Percy Ivy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2011
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors
Patricia M LoRusso, Charles M Rudin, Josina C Reddy, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
Amita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2021
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Florence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2016
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Daniel D Von Hoff, Monica M Mita, Ramesh K Ramanathan, et al.
Page
of 28